Abiopharma

🔍 Adatia Karim (Executive)

Company: INSIGHT ENTERPRISES INC (NSIT)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 9,982 shares of Restricted Stock (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: false | shares_owned_after: 9,982.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 9,982 shares of Restricted Stock (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: false | shares_owned_after: 9,982.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 2,329 shares of Restricted Stock (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: false | shares_owned_after: 2,329.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Common Stock of Insight Enterprises, Inc.
• F2: The number of restricted stock units earned is subject to the achievement of the absolute share price goals over a three year measurement period as defined in the grant agreement. Once earned, the restricted stock units will vest on December 15, 2028.
• F3: The restricted stock units were granted on Apil 15, 2026 with vesting to occur in three equal annual installments beginning December 15, 2026.
• F4: The restricted stock units were granted on April 15, 2026 with vesting to occur in three equal annual installments beginning February 20, 2027.